The CD25 monoclonal antibody inhibits the proliferation of interleukin-2 (IL-2)-dependent human continuous T-cell lines. It blocks the human T-cell receptor for IL-2 by binding to the alpha-chain of the IL-2 receptor. Anti-CD25-SAP specifically eliminates cells expressing mouse CD25 and is potently cytotoxic to mouse activated T-cells. Anti-CD25 immunotoxins have been shown to remove activated T lymphocytes in culture, and can be used to understand the role of this population in its various processes in the immune system. It has also been suggested for clinical use in the treatment of T-cell leukemias and lymphomas.
To eliminate CD25-expressing cells in human, use Anti-CD25-SAP human (Cat. #IT-24).
Anti-CD25-SAP specifically eliminates cells that express the murine Interleukin-2 (IL-2) receptor.
To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols